17 results about "Polyoma virus" patented technology

Disclosed herein are compositions and methods for eliciting an immune response to an antigen. More particularly, disclosed herein are compositions suitable for eliciting immune responses to a plurality of viruses, including Epstein-Ban vims (EBV), cytomegalovirus (CMV), polyoma BK vims (BKV), polyoma JC vims (JCV), and adenovims (Adv), and methods of using such compositions for treatment and prophylaxis.

This invention discloses a primer-probe combination, detection method, and kit for detecting human polyomaviruses, belonging to the field of molecular biology. The primer-probe combination includes primers with sequences as shown in SEQ ID NO. 1-28 and probes with sequences as shown in SEQ ID NO. 29-31. The detection method and kit constructed using this combination can simultaneously detect 14 human polyomaviruses (BKPyV, JCPyV, KIPyV, WUPyV, MCPyV, HPyV6, HPyV7, TSPyV, HPyV9, MWPyV, STLPyV, HPyV12, NJPyV, and LIPyV) in the same reaction tube. The human polyomavirus detection scheme provided by this invention has advantages such as wide coverage, high specificity, high sensitivity, and strong robustness, and is of great significance for the safety and quality control of biological products, especially cell products.

The invention is applicable to the technical field of biological medicines, and provides a fully human anti-BK polyoma virus IgG1 monoclonal antibody BKAb04 and a preparation method thereof, the antibody BKAb04 is specifically bound with a BK polyoma virus capsid protein VLP or a capsid protein monomer VP1 protein thereof; the amino acid sequence comprises an HCDR1 shown as SEQ ID NO: 2, an HCDR2 shown as SEQ ID NO: 3, a heavy chain variable region of an HCDR3 shown as SEQ ID NO: 4, an LCDR1 shown as SEQ ID NO: 5, an LCDR2 shown as SEQ ID NO: 6 and a light chain variable region of an LCDR3 shown as SEQ ID NO: 7. The prepared full-human monoclonal antibody BKAb04 for resisting the BK polyomavirus IgG1 can be specifically combined with BK polyomavirus capsid protein, so that the BK polyomavirus is prevented from infecting host cells, and the full-human monoclonal antibody BKAb04 can be used for preparing medicines for preventing or treating BK polyomavirus infection and related complications thereof.

Immunogenic compositions and methods of use thereof, for eliciting an immune response against one or more virally driven cancers are described. The compositions typically include one or more viral antigens expressed in the virally driven cancers, or a nucleic acid encoding the same, and optionally one or more adjuvants. Preferably, the compositions include nucleic acids (e.g., mRNA) encoding one or more viral antigens. Exemplary antigens include those derived from a truncated form of the viral Large T Antigen (LTA) or Small T Antigen (STA) of Merkel Cell Polyomavirus (MCPyV), or E2, E5, or E6 proteins of HPV. Pharmaceutical compositions and dosages including one or more of the compositions and an excipient, and methods of immunizing subjects and priming and engineer T cells for use in adoptive therapy are also provided.

This invention provides a dosage regimen for the treatment of BK or JC polyomavirus infection in human subjects. [Solution] The administration regimen includes the steps of (a) parenterally administering a dose of an antibody or antigen-binding fragment that specifically binds to the VP1 protein of the polyomavirus to the subject; (b) measuring the serum or tissue concentration of the antibody or antigen-binding fragment in the subject; and (c) measuring the serum or tissue trough concentration (C trough The administration regimen includes the step of administering a further dose of the antibody or its antigen-binding fragment before the concentration drops to less than approximately 3-860 μg / mL, wherein the concentration of the antibody or its antigen-binding fragment in the serum or tissue during the treatment is reduced to the C trough Maintain a higher position.

The present patent application relates to the fields of antibodies and polyomaviruses. More specifically, the present patent application relates to a human monoclonal antibody, or antigen- binding fragment thereof, directed against a polyomavirus, in particular BKV, and that is useful in the treatment of an infection by said polyomavirus or associated-disorder thereof.

The present patent application relates to the fields of antibodies and polyomaviruses. More specifically, the present patent application relates to a human monoclonal antibody, or antigen-binding fragment thereof, directed against a polyomavirus, in particular BKV, and that is useful in the treatment of an infection by said polyomavirus or associated-disorder thereof.

The invention relates to the discovery of the virus consisting of Opisthorhabdovirus (ORV), Opisthorphenuilivirus (OPLV), Opisthorsivirus (OSV),Clonorsivirus (CSV), Clonorhabdovirus (CRV), Clonorphenuilivirus (CPLV), Schistohaemavirus (ShV), Schistohaematogalivirus (ShTLV), Schistohaemendornavirus (ShMV) and Schistorhabovirus (ShRV) from the Class I carcinogen trematodes Schistosoma haematobium, Opisthorchis viverrini and Clonorchis sinensis and provide evidence of fluke-borne infection of parasitized vertebrate hosts.. The invention provides viruses, nucleic acids, proteins, peptides, and antibodies useful for diagnosis, treatment, and prevention of viral infection and associated diseases.

The present patent application relates to the fields of antibodies and polyomaviruses. More specifically, the present patent application relates to a human monoclonal antibody, or antigen-binding fragment thereof, directed against a polyomavirus, in particular BKV, and that is useful in the treatment of an infection by said polyomavirus or associated-disorder thereof.

Compounds, methods, and compositions for treating or preventing viral infections using nucleoside compounds. The nucleoside compounds have increased antiviral activity potential with the result of inhibiting at least one of flaviviruses, herpesviruses, polyomaviruses, alphaviruses, enteroviruses, filoviruses matonaviruses, phenuiviruses, Hepatitis B virus, and / or coronaviruses.

The invention relates to the technical field of molecular detection, in particular to deoxyribozyme for detecting BK polyoma virus and application of deoxyribozyme. The deoxyribozyme comprises a catalytic core and a binding arm connected with the 5'end and / or the 3 'end of the catalytic core, wherein the catalytic core has the activity of cutting nucleic acid. The invention further provides a method for detecting the BK polyomavirus, the method comprises the step that a sample to be detected makes contact with the deoxyribozyme, by means of the nucleic acid detection method, the BK polyomavirus as low as 0.1 aM can be detected, and extremely high sensitivity and specificity are achieved.

The present patent application relates to the fields of antibodies and polyomaviruses. More specifically, the present patent application relates to a human monoclonal antibody, or antigen-binding fragment thereof, directed against a polyomavirus, in particular BKV, and that is useful in the treatment of an infection by said polyomavirus or associated-disorder thereof.

The application discloses a primer pair for detecting an avian polyomavirus large T gene and application thereof, and belongs to the technical field of biological detection. Nucleotide sequences of forward and reverse primers of the primer pair are shown in SEQ ID NO. 1 and SEQ ID NO. 2 in sequence. The application provides a primer pair capable of specifically detecting the avian polyomavirus large T gene and an application method, the primer pair can specifically amplify the avian polyomavirus, and does not have cross reaction with nucleic acids of other viruses, is high in specificity, can realize rapid and accurate detection of the avian polyomavirus through a real-time fluorescent RPA detection method, has the advantages of simple operation, low cost, high sensitivity and low false positive rate, and solves problems of high detection cost, long time, high requirement for detection personnel, need for professional training, only suitable for auxiliary diagnosis of a laboratory and incapability of popularization and application of existing detection methods.

Provided herein are monoclonal antibodies targeting VP1 of polyomaviruses including BK virus. Also provided are methods of treating or preventing polyomavirus infections using one or more antibodies.

The invention relates to antisense molecules and methods for modulating splicing of polyomavirus T antigen pre-mRNA. In one aspect the invention relates to an antisense oligonucleotide 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length which comprises a sequence that is the reverse complement of a contiguous stretch of at least 12 nucleobases of a polyomavirus T-antigen pre-mRNA and which antisense oligonucleotide can modulate splicing of said T-antigen pre-mRNA in a cell.

The invention is applicable to the technical field of biological medicines, and provides a fully human anti-BK polyoma virus IgG1 monoclonal antibody BKAb03 and a preparation method thereof, and the antibody BKAb03 is specifically bound with a BK polyoma virus capsid protein VLP or a capsid protein monomer VP1 protein thereof; the amino acid sequences of the HCDR1, the HCDR2 and the heavy chain variable region of the HCDR3 are as shown in SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, and the light chain variable region comprises the LCDR1 as shown in SEQ ID NO: 5, the LCDR2 as shown in SEQ ID NO: 6 and the LCDR3 as shown in SEQ ID NO: 7. The antibody prepared by the invention can be used for preparing medicines for treating or preventing BK polyoma virus infection and / or BK polyoma virus related complications.

Provided herein are methods and compositions related to polyomavirus epitopes useful in the treatment of cancer or polyomavirus infection.